Get your doctor to read this article. We absolutely need to know what drugs might prevent us from neuroplastically changing our brains. The abstract is worthless.
A prospective test of the late effects of potentially antineuroplastic drugs in a stroke rehabilitation study
Background
Extensive
data, primarily from animal studies, suggest that several classes of
drugs may have antineuroplastic effects that could impede recovery from
brain injury or reduce the efficacy of rehabilitation.
Aims
The
Locomotor Experience Applied Post-Stroke trial, a randomized controlled
study of 408 subjects that tested the relative efficacy of two
rehabilitation techniques on functional walking level at one-year
poststroke, provided us the opportunity to prospectively assess the
potential antineuroplastic effects of several classes of drug.
Methods
Subjects
were randomized to receive one of the two rehabilitation therapies at
two-months poststroke. Drugs taken were recorded at time of
randomization. Outcome was assessed at one-year poststroke. Regression
models were used to determine the amount of variance in success in
improving functional walking level, gains in walking speed, and declines
in lower extremity, upper extremity, and cognitive impairment accounted
for by α1 noradrenergic blockers + α2 noradrenergic agonists, benzodiazepines, voltage-sensitive sodium channel anticonvulsants, and α2δ voltage-sensitive calcium channel blockers.
Results
The
maximum variance accounted for by any drug class was 1·66%. Drug
effects were not statistically significant when using even our most
lenient standard for correction for multiple comparisons.
Conclusions
Drugs
in the classes we were able to assess do not appear to exert a
clinically important effect on outcome over the period between two- and
12 months poststroke. However, the potential antineuroplastic effects of
certain drugs remain an incompletely settled scientific question.
No comments:
Post a Comment